TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CASTRO1 - Study on CRP Apheresis After Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischaemic stroke with determination of infarct size by imaging (MRI)~* NIHSS 1-24~* CRP increase ≥ 5 mg/l within presumed 72 hours after stroke and/or CRP value \> 10 mg/l~* written informed consent of the patient or his legal representative~Exclusion Criteria:~* age \< 18 years~* Severe dysphagia (danger of aspiration pneumonia)~* Clinical or laboratory evidence of a severe systemic infection~* Participation in other interventional studies~* Contraindications against apheresis therapy~* Modified Rankin Scale (mRS) before index event ≥ 3~* Intracranial hemorrhage~* Epileptic seizure in the context of the acute event~* Pregnancy, lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apheresis group (Type: EXPERIMENTAL): 10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts within 72 hours after infarction or, in case of an unclear time window, within presumed 72 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is \<10 mg/l or if the patient has been discharged from hospital.~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours.
- Control group (Type: NO_INTERVENTION): 10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxidative Stress Links Aging, Activity, and Mobility Limitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women aged either between 18 - 30 years (young group) and \>70 years (old group)~* Free of overt disease. Subjects will be non-obese (BMI \< 30) and have plasma glucose concentrations \< 7.0 mmol/L under fasting conditions and \< 11.1 mmol/L at 120 minutes of an oral glucose tolerance test (OGTT)~* Subjects will be sedentary, defined here as no regular physical activity for at least the prior 2 years~* Candidates must have no orthopedic limitations that would prohibit them from performing cycle or knee-extensor exercise~* All women will be postmenopausal (either natural or surgical) defined as a cessation of menses for at least 2 years, and in women without a uterus, follicle stimulating hormone (FSH) \> 40 IU/L~Exclusion Criteria:~* Candidates demonstrating dyslipidemia based on the National Cholesterol Education Program Guidelines of plasma total cholesterol \> 240 mg/dl with LDL-cholesterol \> 160 mg/dl will be excluded from participation~* Candidates who smoke or are taking medications (blood pressure medications, statins, antioxidants etc.) that could influence the results of the study will not be eligible~* In terms of diet, subjects will be asked to maintain a dietary record for one week prior to the pre-screening and if this reveals a diet that differs substantially from the typical average diet in both the young and old, the subject will not be eligible~* Women currently taking hormone replacement therapy (HRT) in the preceding year will be excluded from the proposed studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: OTHER): Young healthy men and women aged 18-30
- Arm 2 (Type: OTHER): Older healthy men and women aged \>70.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed adenocarcinoma of the pancreas~* Unresectable disease based on the following imaging criteria (table 1)~  * extrapancreatic extension~ * tumor involvement of the SMA or celiac axis~ * evidence of occlusion of the SMV-portal vein confluence~* KPS \> 50 (ECOG 0-2)~* Age \>18 years~* Women of childbearing age and male participants must practice adequate contraception (hormonal or barrier method of birth control; abstinence) prior to and throughout study treatment.~* Life expectancy \> 3 months~* Ability to understand and the willingness to sign a written informed consent.~* Note that patients with metastatic disease are eligible if it is felt that the patients will benefit from local control of the primary disease.~* Disease that is measureable or evaluable for response endpoint per RECIST~Exclusion Criteria:~* Prior radiotherapy to the upper abdomen~* Resectable or borderline resectable pancreas cancer. Note that these patients are eligible for a separate study looking at radiosurgery for borderline resectable pancreas cancer~* Severe comorbidity rendering a candidate ineligible for chemotherapy or radiation, Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Patients of childbearing age who are unwilling or unable to practice contraception~* Inability to undergo MRI or CT with contrast for treatment planning~* Patients may not be receiving any other investigational nor commercial agents with therapeutic intent to treat pancreatic cancer while on this trial. Note that patients can have had previous investigational therapy but cannot have this concurrently with this protocol treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Chemotherapy:~Gemcitabine 1000 mg/m2 and Abraxane 125 mg/m2 weekly x3 of 28 day cycle~Radiation:~20-55 GY over 5 fractions~Dosing schedule: 3 cycles of chemotherapy, followed by CyberKnife, followed by 3 additional cycles of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age \> 50-80 years~* Prostate gland size 50-100g~* Failure of nonoperative therapy~* IPSS 8+~* FR \<15ml/s~* PVR \<250~* If PVR is 250-400 then pre-operative urodynamics will be indicated~* Language: English, Spanish, Haitian Creole, French, Portuguese~* Willing to randomize~Exclusion Criteria:~* Neurogenic bladder~* PVR \>400ml~* IPSS \<8~* FR \>15ml/Indwelling catheter~  - History of prostate cancer~* History of urethral stricture or vesicourethral anastomotic stricture~* Unable to be placed in lithotomy position~* Unable to undergo general or spinal anesthesia~* Unable to consent~* Untreated or uncorrected coagulopathy

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ProTouch Laser Enucleation of Prostate (Type: ACTIVE_COMPARATOR): The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
- Transurethral Resection of Prostate (Type: ACTIVE_COMPARATOR): The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, aged ≥18 years at baseline;~* Identify as a man who has sex with a men (MSM);~* HIV-positive; laboratory documentation of HIV-1 infection;~* For those on combination antiretroviral therapy (cART), the participant must be on a stable regimen;~* An ability to give informed consent;~* An ability to attend clinic for follow-up, including possible HRA and biopsy;~* AIN-2 or -3 found on biopsy of anal canal lesion(s);~* Willingness to be randomized to undergo ablative therapy or active surveillance.~Exclusion Criteria:~* Current or prior history of cancer of the anogenital regions (e.g. penile, anal, or rectal).;~* Previous treatment of high grade dysplasia;

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ablative therapy (Type: EXPERIMENTAL): Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
- Active Surveillance (Type: ACTIVE_COMPARATOR): The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Optisure Lead Post Approval Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Eligible patients will meet all of the following:~1. Have an approved indication, as per ACC/AHA/HRS/ESC guidelines, for implantation of an ICD or CRT-D system for treatment of heart failure or life-threatening ventricular tachyarrhythmia(s).~2. Have been implanted with a St. Jude Medical Optisure lead in the last 30 days or are scheduled for an Optisure lead implant.~3. Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations.~4. Are 18 years or above, or of legal age to give informed consent specific to state and national law.~Exclusion Criteria:~Patients will be excluded if they meet any of the following:~1. Enrolled or intend to participate in a clinical drug and/or device study, which could confound the results of this trial as determined by SJM, during the course of this clinical study.~2. Have a life expectancy of less than 5 years due to any condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- St. Jude Medical Optisure Lead (Type: None): Patients implanted with St. Jude Medical Optisure Lead

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Training in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 45 years old~* mild to moderate persistent asthma (GINA classification)~* stabilized asthma~* physical activity level between 5 and 11 (Baecke and coll, 1982)~* no contra-indication for physical training~Exclusion Criteria:~* cardiovascular pathology~* metabolic pathology~* traumatic pathology~* BMI≥30~* tobacco~* diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- CA (Type: EXPERIMENTAL): Exercise training with alternate load
- CC (Type: ACTIVE_COMPARATOR): Exercise training with constant load

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Teachable Moment Brief Intervention for Suicide Attempt Survivors in an Inpatient Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
TMBI \& TAU (data collection at Laureate Psychiatric Clinic and Hospital \[LPCH\])~Inclusion:~-admitted to LPCH subsequent to a suicide attempt~Exclusion:~* acute psychosis,~* inability to read English, or~* taking narcotic or opioid pain medication~CCG (data collection in the Psychophysiology Laboratory for Affective Neuroscience \[PLAN\] on the University of Tulsa campus)~Exclusion:~* acute psychosis,~* current suicide ideation,~* history of self-harm,~* inability to read English, or~* taking narcotic or opioid pain medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Teachable Moment Brief Intervention (Type: EXPERIMENTAL): The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
- Treatment as Usual (TAU) (Type: NO_INTERVENTION): Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
- Community Control Group (CCG) (Type: NO_INTERVENTION): Patients will engage in a rest period before completing the post-assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Planning or currently on chronic lubiprostone therapy (chronic is defined as at least one 24 microgram capsule by mouth every other day~* Body mass index (BMI) of less than 22 for females and less than 23 for males at the initiation of chronic lubiprostone therapy~* Initiation of chronic lubiprostone therapy within 1 month of enrollment~* Age over 18~* Currently taking a multivitamin~Exclusion Criteria:~* History of noncompliance with medications and other CF therapies~* History of hospital admissions for CF exacerbations of ≥2 in the last 6 months~* FEV1 les than 40% of expected (severe dysfunction) at most recent assessment in the ambulatory setting~* Currently registered on a lung transplant waiting list~* Any other condition, in the opinion of the investigators, that interferes with the ability of the study subject to comply with study requirements, confers significant risk, or limits the ability of the subject to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Only group (Type: None): adult cystic fibrosis patients who are not at goal body mass index and have started lubiprostone therapy within one month of study enrollment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Clonidine for Lumbosacral Radiculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residents 18 years or older of Olmsted or contiguous counties and identified as having an acute unilateral radicular syndrome of less than 3 months duration (leg pain\>back, discogenic cause, one or more of the following:~  * Positive Straight Leg Raise (SLR) test~ * Myotomal weakness~ * Dermatomal sensory loss) and with concordant~ * Confirmatory findings on recent MRI or CT myelogram~Exclusion Criteria:~* History of recent spinal trauma~* Cauda equina syndrome (This is a serious neurologic condition in which there is acute loss of function of the lumbar plexus, neurologic elements of the spinal canal below the termination of the spinal cord.)~* Progressive neurological deficit~* Motor deficit~* Pathological or infectious etiology~* Involvement in workers' compensation claim~* History of adverse reaction to corticosteroids, local anesthetic or clonidine~* History of one or more corticosteroid injection(s) (equivalent to 40 mg of triamcinolone acetate) in the preceding 4 months~* Pregnant~* Severe medical disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Clonidine (Type: EXPERIMENTAL): Transforaminal epidural clonidine injection
- Steroid (Type: ACTIVE_COMPARATOR): Transforaminal epidural steroid injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Structured Weight Loss Program in Overweight Women With a History of Recurrent Pregnancy Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Unexplained recurrent pregnancy loss (2 or more prior miscarriages)~2. BMI \>=25 kg/m2~3. Prepared to take 3 months ¡®time out¡± from attempting to conceive~4. Ability to attend a one hour initial, then 30 minute follow-up nutrition/monitoring session - once per week for one month, then every other week for 2 months, then once then once per month for 3 months.~Exclusion Criteria:~1. Age \>=40 years~2. Diagnosis of Type 1 or Type 2 Diabetes as defined by a fasting glucose \>=126, or 2 hour glucose \>=200 by a 75 gram oral glucose challenge~3. Presence of an endocrine condition such as hyperprolactinemia, Cushing¡-s syndrome or untreated thyroid disease (defined as a TSH outside of the laboratory determined normal range)~4. Desire to continue attempts to conceive for the duration of the program~5. History of bariatric surgery~6. Use of over-the-counter or prescribed weight loss medications with the exception of metformin~7. Enrollment in another clinical trial (excluding surveys)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- Structured Weight Loss (Type: EXPERIMENTAL): Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
- Routine Weight Loss Counseling (Type: ACTIVE_COMPARATOR): Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fresh Vs Frozen Surgical Sperm in IVF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females age \< 42 with an indication for IVF~* Females with lowest AMH level 1.2 ng/mL or higher~* Females with FSH \< 13 mIU/mL~* Sperm obtained via Surgical retrieval (any type) for IVF only~* Use of comprehensive chromosome screening (CCS) to screen embryos for aneuploidy~* BMI \< 35~* Baseline antral follicle count of \> 8~* Single embryo transfers only~Exclusion Criteria:~* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.~* Contraindication to IVF~* Clinical indication for preimplantation genetic diagnosis (PGD) (i.e., screening for single gene disorder, chromosomal translocation, or any other disorders requiring detailed embryo genetic analysis)~* Fewer than 4 mature oocytes retrieved (will not randomize)~* Male partner with non-obstructive azoospermia~* Male partner with any Karyotype other than 46,XY~* Male partner with history of spinal cord injury~* Male partner with Kallman's syndrome~* History of chronic oligomenorrhea~* History of hydrosalpinges or adnexal mass~* History of endometrial insufficiency (max endometrial thickness \< 7mm)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fresh surgical testicular sperm (Type: NO_INTERVENTION): Fresh, surgically obtained testicular sperm
- Frozen surgical testicular sperm (Type: EXPERIMENTAL): Surgically obtained testicular sperm that will undergo slow freezing and thawing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues